Celcuity Completes $24M Public Offering

Celcuity, a clinical stage biotechnology company translating discoveries of new cancer sub-types into third-generation diagnostics and expanded therapeutic options for cancer patients, completed a $24 million public offering underwritten by Craig-Hallum. Faegre Drinker advised Craig-Hallum in the transaction and previously represented the underwriters in Celcuity’s IPO.